Q2 EPS Estimates for Sutro Biopharma Lifted by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – HC Wainwright raised their Q2 2026 earnings estimates for Sutro Biopharma in a research note issued on Friday, May 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($2.33) for the quarter, up from their prior forecast of ($2.58). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($9.04) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q3 2026 earnings at ($2.32) EPS, Q4 2026 earnings at ($2.32) EPS, FY2026 earnings at ($9.30) EPS, FY2027 earnings at ($4.92) EPS, FY2028 earnings at ($7.29) EPS, FY2029 earnings at ($5.09) EPS and FY2030 earnings at ($5.23) EPS.

Other research analysts have also recently issued reports about the stock. Citigroup reaffirmed an “outperform” rating on shares of Sutro Biopharma in a report on Friday, April 17th. Mizuho set a $50.00 target price on shares of Sutro Biopharma and gave the company an “outperform” rating in a report on Thursday, April 30th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Sutro Biopharma from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Wells Fargo & Company raised shares of Sutro Biopharma from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $8.00 to $27.00 in a report on Tuesday, March 24th. Finally, Leerink Partners set a $43.00 target price on shares of Sutro Biopharma and gave the company an “outperform” rating in a report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $48.25.

Sutro Biopharma Trading Down 11.5%

Shares of Sutro Biopharma stock opened at $34.48 on Tuesday. Sutro Biopharma has a 12-month low of $6.74 and a 12-month high of $43.85. The stock has a market cap of $571.33 million, a PE ratio of -2.00 and a beta of 1.63. The company has a 50-day moving average of $29.43 and a two-hundred day moving average of $18.50.

Sutro Biopharma (NASDAQ:STRO) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) EPS for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The company had revenue of $14.52 million for the quarter, compared to analysts’ expectations of $8.89 million.

Hedge Funds Weigh In On Sutro Biopharma

Hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new position in shares of Sutro Biopharma in the 3rd quarter valued at $152,000. Bank of America Corp DE lifted its holdings in Sutro Biopharma by 51.3% in the 3rd quarter. Bank of America Corp DE now owns 119,434 shares of the company’s stock worth $104,000 after buying an additional 40,488 shares in the last quarter. Strs Ohio acquired a new position in Sutro Biopharma in the 1st quarter worth $99,000. State of Tennessee Department of Treasury acquired a new position in Sutro Biopharma in the 4th quarter worth $86,000. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Sutro Biopharma in the 2nd quarter worth about $82,000. Institutional investors and hedge funds own 96.99% of the company’s stock.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.